[
    [
        {
            "time": "2019-12-31",
            "original_text": "【面包财报】天坛生物：2019年归母净利润6.11亿元，同比增长19.95%",
            "features": {
                "keywords": [
                    "天坛生物",
                    "归母净利润",
                    "同比增长",
                    "2019年年报"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【面包财报】天坛生物：2019年归母净利润6.11亿元，同比增长19.95%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-12-31",
            "original_text": "天坛生物（600161）：业绩符合预期，即将迈入快速增长期【2019年年报点评|西南医药朱国广/杜向阳团队】",
            "features": {
                "keywords": [
                    "天坛生物",
                    "业绩符合预期",
                    "快速增长期",
                    "西南医药",
                    "年报点评"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物（600161）：业绩符合预期，即将迈入快速增长期【2019年年报点评|西南医药朱国广/杜向阳团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]